We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
sensitivity and specificity) of the assays developed by AI are equivalent to or even better than that of those manually developed," and also added, "Only four (4) days were sufficient by the AI system to successfully develop two 8-plex assays
CEO and cofounder of Standigm, Jinhan Kim, is introducing the new AI based drug discovery services, ‘Expander’ and ‘Hunter’ at the Bio-Europe 2017 in Berlin, Germany. Photo credit: Standigm
Scientists at MIT’s Computer Science and Artificial Intelligence Laboratory have developed a machine learning AI system that is able diagnose patients with breast cancer 97% of the time.